Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response

Skip Nav Destination

Acta Haematol (2010) 124 (1): 46–48.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia

Mathieu Meunier
Sophie Park

eJHaem (2022) 3 (4): 1091.

Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes

Julia Stomper
Paulina Richter-Pechanska
Dietmar Pfeifer
Immacolata Andolfo
Achille Iolascon
Martina U. Muckenthaler
Michael Lübbert

Blood Advances (2022) 6 (11): 3551.

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS

Heather A. Leitch
Rena Buckstein
Nancy Zhu
Thomas J. Nevill
Karen W.L. Yee
Brian Leber
Mary-Margaret Keating
Eve St. Hilaire
Rajat Kumar
Robert Delage
Michelle Geddes
John M. Storring
April Shamy
Mohamed Elemary
Richard A. Wells

Leukemia Research (2018) 74: 21.

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Mathieu Meunier
Sarah Ancelet
Christine Lefebvre
Josiane Arnaud
Catherine Garrel
Mylène Pezet
Yan Wang
Patrice Faure
Gautier Szymanski
Nicolas Duployez
Claude Preudhomme
Denis Biard
Benoit Polack
Jean-Yves Cahn
Jean Marc Moulis
Sophie Park

Oncotarget (2017) 8 (62): 105510.

New insights into transfusion-related iron toxicity: Implications for the oncologist

John B. Porter
Theo de Witte
M. Domenica Cappellini
Norbert Gattermann

Critical Reviews in Oncology/Hematology (2016) 99: 261.

Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase

Masayo Yamamoto
Hiroki Tanaka
Yasumichi Toki
Mayumi Hatayama
Satoshi Ito
Lynda Addo
Motohiro Shindo
Katsunori Sasaki
Katsuya Ikuta
Takaaki Ohtake
Mikihiro Fujiya
Yoshihiro Torimoto
Yutaka Kohgo

International Journal of Hematology (2016) 104 (4): 491.

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

Roberto Latagliata
Chiara Montagna
Raffaele Porrini
Ambra Di Veroli
Sabrina Crescenzi Leonetti
Pasquale Niscola
Fabrizio Ciccone
Antonio Spadea
Massimo Breccia
Luca Maurillo
Angela Rago
Francesca Spirito
Michele Cedrone
Marianna De Muro
Marco Montanaro
Alessandro Andriani
Antonino Bagnato
Enrico Montefusco
Giuliana Alimena

European Journal of Haematology (2016) 96 (6): 643.

Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy

Harpreet Kochhar
Chantal S. Leger
Heather A. Leitch

Case Reports in Hematology (2015) 2015: 1.

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms

Massimo Breccia
Maria Teresa Voso
Maria Antonietta Aloe Spiriti
Susanna Fenu
Luca Maurillo
Francesco Buccisano
Agostino Tafuri
Giuliana Alimena

Annals of Hematology (2015) 94 (5): 771.

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

David P. Steensma
Norbert Gattermann

Best Practice & Research Clinical Haematology (2013) 26 (4): 431.

Efficacy and safety of deferasirox in myelodysplastic syndromes

Massimo Breccia
Giuliana Alimena

Annals of Hematology (2013) 92 (7): 863.

8. Iron Overload by Blood Transfusion

Takahiro Suzuki
Keiya Ozawa

Nihon Naika Gakkai Zasshi (2012) 101 (7): 1986.

Iron Chelation Therapy with Deferasirox Results in Recovery of Hematopoiesis in a Child with Aplastic Anemia

Jae Wook Lee
Pil-Sang Jang
Nack-Gyun Chung
Bin Cho
Dae-Chul Jeong
Hack-Ki Kim

Pediatric Hematology and Oncology (2011) 28 (8): 718.

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

Roberto Guariglia
Maria Carmen Martorelli
Oreste Villani
Giuseppe Pietrantuono
Giovanna Mansueto
Fiorella D’Auria
Vitina Grieco
Gabriella Bianchino
Rosa Lerose
Giovanni Battista Bochicchio
Pellegrino Musto

Leukemia Research (2011) 35 (5): 566.

Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response

INFORMATION

ABOUT US

SERVICES FOR

Karger International

Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response

This Feature Is Available To Subscribers Only